Physician profile
Stephen A White
NPI 1740487305
$11,206.45
in general payments reported to CMS, 2019-2025
50 companies · $1,006 in 2025
The $1,006 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,212 · 2020: $1,433 · 2021: $1,932 · 2022: $2,023 · 2023: $1,710 · 2024: $1,890 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,481 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,480.90 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $124.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,083.74 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,343.88 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $858.78 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $796.61 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Bayer Healthcare Pharmaceuticals INC. | $552.42 | 2022-2025 | |
| Exact Sciences Corporation | $442.29 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $426.47 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $344.94 | 2020-2025 | Rexulti, Nuedexta |
| Janssen Pharmaceuticals, INC | $307.33 | 2019-2023 | Xarelto |
| Avanir Pharmaceuticals, INC. | $300.58 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $291.90 | 2022-2025 | Ingrezza |
| Dexcom, INC. | $242.59 | 2021-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $226.19 | 2020-2024 | Nexletol |
| Lilly USA, LLC | $223.78 | 2019-2023 | Trulicity, Humalog, Basaglar |
| Eisai INC. | $221.39 | 2020-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.